{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:24:34Z","timestamp":1791239074835,"version":"4.1.0"},"reference-count":55,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,11]]},"abstract":"ABSTRACT<\/jats:title>\n \n Epidemiological cutoff values (ECVs) for the\n Cryptococcus neoformans-Cryptococcus gattii<\/jats:named-content>\n species complex versus fluconazole, itraconazole, posaconazole, and voriconazole are not available. We established ECVs for these species and agents based on wild-type (WT) MIC distributions. A total of 2,985 to 5,733 CLSI MICs for\n C. neoformans<\/jats:named-content>\n (including isolates of molecular type VNI [MICs for 759 to 1,137 isolates] and VNII, VNIII, and VNIV [MICs for 24 to 57 isolates]) and 705 to 975 MICs for\n C. gattii<\/jats:named-content>\n (including 42 to 260 for VGI, VGII, VGIII, and VGIV isolates) were gathered in 15 to 24 laboratories (Europe, United States, Argentina, Australia, Brazil, Canada, Cuba, India, Mexico, and South Africa) and were aggregated for analysis. Additionally, 220 to 359 MICs measured using CLSI yeast nitrogen base (YNB) medium instead of CLSI RPMI medium for\n C. neoformans<\/jats:named-content>\n were evaluated. CLSI RPMI medium ECVs for distributions originating from at least three laboratories, which included \u226595% of the modeled WT population, were as follows: fluconazole, 8 \u03bcg\/ml (VNI,\n C. gattii<\/jats:named-content>\n nontyped, VGI, VGIIa, and VGIII), 16 \u03bcg\/ml (\n C. neoformans<\/jats:named-content>\n nontyped, VNIII, and VGIV), and 32 \u03bcg\/ml (VGII); itraconazole, 0.25 \u03bcg\/ml (VNI), 0.5 \u03bcg\/ml (\n C. neoformans<\/jats:named-content>\n and\n C. gattii<\/jats:named-content>\n nontyped and VGI to VGIII), and 1 \u03bcg\/ml (VGIV); posaconazole, 0.25 \u03bcg\/ml (\n C. neoformans<\/jats:named-content>\n nontyped and VNI) and 0.5 \u03bcg\/ml (\n C. gattii<\/jats:named-content>\n nontyped and VGI); and voriconazole, 0.12 \u03bcg\/ml (VNIV), 0.25 \u03bcg\/ml (\n C. neoformans<\/jats:named-content>\n and\n C. gattii<\/jats:named-content>\n nontyped, VNI, VNIII, VGII, and VGIIa,), and 0.5 \u03bcg\/ml (VGI). The number of laboratories contributing data for other molecular types was too low to ascertain that the differences were due to factors other than assay variation. In the absence of clinical breakpoints, our ECVs may aid in the detection of isolates with acquired resistance mechanisms and should be listed in the revised CLSI M27-A3 and CLSI M27-S3 documents.\n <\/jats:p>","DOI":"10.1128\/aac.01115-12","type":"journal-article","created":{"date-parts":[[2012,9,5]],"date-time":"2012-09-05T02:53:01Z","timestamp":1346813581000},"page":"5898-5906","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":231,"title":["Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole, and Voriconazole"],"prefix":"10.1128","volume":"56","author":[{"given":"A.","family":"Espinel-Ingroff","sequence":"first","affiliation":[{"name":"VCU Medical Center, Richmond, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. I.","family":"Aller","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Valme, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Canton","sequence":"additional","affiliation":[{"name":"Unidad de Microbiologia Experimental, Hospital Universitario La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. R.","family":"Casta\u00f1\u00f3n-Olivares","sequence":"additional","affiliation":[{"name":"Universidad Nacional Aut\u00f3noma de Mexico, Distrito Federal, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Chowdhary","sequence":"additional","affiliation":[{"name":"Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cordoba","sequence":"additional","affiliation":[{"name":"Departamento de Micolog\u00eda, Instituto Nacional de Enfermedades Infecciosas, ANLIS \u201cDr. Carlos G. Malbr\u00e1n,\u201d Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cuenca-Estrella","sequence":"additional","affiliation":[{"name":"Servicio de Micolog\u00eda, Centro Nacional de Microbiolog\u00eda, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fothergill","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Fuller","sequence":"additional","affiliation":[{"name":"The University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Govender","sequence":"additional","affiliation":[{"name":"National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Hagen","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. T.","family":"Illnait-Zaragozi","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine Pedro Kouri, Havana, Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Johnson","sequence":"additional","affiliation":[{"name":"The HPA Mycology Reference Laboratory, Kingsdown, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kidd","sequence":"additional","affiliation":[{"name":"Women's and Children's Hospital, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lass-Fl\u00f6rl","sequence":"additional","affiliation":[{"name":"The Innsbruck Medical University, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. R.","family":"Lockhart","sequence":"additional","affiliation":[{"name":"Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Martins","sequence":"additional","affiliation":[{"name":"The Adolfo Lutz Institute Public Health Reference Center, S\u00e3o Paulo and Rio Claro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. F.","family":"Meis","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Radboud University Medical Centre, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S. C.","family":"Melhem","sequence":"additional","affiliation":[{"name":"The Adolfo Lutz Institute Public Health Reference Center, S\u00e3o Paulo and Rio Claro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ostrosky-Zeichner","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Pelaez","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Faculty of Medicine-Universidad Complutense, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Pfaller","sequence":"additional","affiliation":[{"name":"University of Iowa, Iowa City, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. A.","family":"Schell","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"St-Germain","sequence":"additional","affiliation":[{"name":"Laboratoire de Sant\u00e9 Publique du Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Trilles","sequence":"additional","affiliation":[{"name":"Instituto de Pesquisa Clinica Evandro Chagas-FIOCRUZ, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Turnidge","sequence":"additional","affiliation":[{"name":"University of Adelaide, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1544-1548.2000"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1086\/517056","article-title":"The hidden danger of fluconazole primary prophylaxis for patients with AIDS","volume":"26","author":"Berg J","year":"1998","unstructured":"BergJ ClancyCJ NguyenMH. 1998. The hidden danger of fluconazole primary prophylaxis for patients with AIDS. Clin. Infect. Dis. 26:186\u2013187.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/507895"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1130-1406(08)70019-6"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.11.3065-3069.2001"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000850"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002205"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3109\/13693780802559031","article-title":"Genotyping of Mexican Cryptococcus neoformans and C. gattii isolates by PCR-fingerprinting","volume":"47","author":"Casta\u00f1\u00f3n-Olivares LR","year":"2009","unstructured":"Casta\u00f1\u00f3n-OlivaresLR. 2009. Genotyping of Mexican Cryptococcus neoformans and C. gattii isolates by PCR-fingerprinting. Med. Mycol. 47:713\u2013721.","journal-title":"Med. Mycol."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10096-004-1136-2","article-title":"In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia","volume":"23","author":"Chandenier JK","year":"2004","unstructured":"ChandenierJK. 2004. In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia. Eur. J. Clin. Microbiol. Infect. Dis. 23:505\u2013508.","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01271-10"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.029025-0"},{"key":"e_1_3_2_13_2","volume-title":"CLSI document M27-A3.","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, third edition. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_14_2","volume-title":"CLSI document M27-S3.","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, third informational supplement. CLSI document M27-S3. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-009-7108-9"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1128\/AAC.01520-05","article-title":"Results obtained with various antifungal susceptibility testing methods do not predict early outcome in patients with cryptococcosis","volume":"50","author":"Dannaoui E","year":"2006","unstructured":"DannaouiE. 2006. Results obtained with various antifungal susceptibility testing methods do not predict early outcome in patients with cryptococcosis. Antimicrob. Agents Chemother. 50:2264\u20132470.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_17_2","first-page":"36","article-title":"In vitro antifungal susceptibility of clinical isolates of Cryptococcus neoformans var. neoformans and C. neoformans var. gattii","volume":"16","author":"DeBedout C","year":"1999","unstructured":"DeBedoutC. 1999. In vitro antifungal susceptibility of clinical isolates of Cryptococcus neoformans var. neoformans and C. neoformans var. gattii. Rev. Iberoam. Micol. 16:36\u201339.","journal-title":"Rev. Iberoam. Micol."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00091\u201310"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1130-1406(08)70027-5"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00536-10"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01730-10"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00686-11"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06252-11"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2008.02021.x"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00048-11"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00746-10"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.06750-11"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir723"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01384-07"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.7.1526"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/jac\/dkg312","article-title":"European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria","volume":"52","author":"Kahlmeter G","year":"2003","unstructured":"KahlmeterG. 2003. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J. Antimicrob. Chemother. 52:143\u2013148.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_32_2","first-page":"1758","article-title":"A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada)","volume":"101","author":"Kidd SE","year":"2004","unstructured":"KiddSE. 2004. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc. Natl. Acad. Sci. U. S. A. 101:1758\u20131763.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/0014-5793(95)00684-2","article-title":"Resistant P45051 AI activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients","volume":"368","author":"Lamb DC","year":"1995","unstructured":"LambDC CorranA BaldwinBC Kwon-ChungJ KellySL. 1995. Resistant P45051 AI activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients. FEBS Lett. 368:326\u2013330.","journal-title":"FEBS Lett."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.02.018"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.5.838"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/376634","article-title":"Amphotericin B: time for a new \u201cgold standard.\u201d","volume":"37","author":"Ostrosky-Zeichner L","year":"2003","unstructured":"Ostrosky-ZeichnerL MarrKA RexJH CohenSH. 2003. Amphotericin B: time for a new \u201cgold standard.\u201d Clin. Infect. Dis. 37:415\u2013425.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032868"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1054\/drup.1999.0090"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1086\/649858"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/jac\/dki393","article-title":"Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans","volume":"56","author":"Perkins A","year":"2005","unstructured":"PerkinsA Gomez-LopezA MelladoE Rodriguez-TudelaJL Cuenca-EstrellaM. 2005. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J. Antimicrob. Chemother. 56:1144\u20131147.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00940-09"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01747-08"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.drup.2010.09.002","article-title":"Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time to harmonization of CLSI and EUCAST broth microdilution methods","volume":"14","author":"Pfaller MA","year":"2010","unstructured":"PfallerMA AndesD DiekemaDJ Espinel-IngroffA SheehanD. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time to harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 14:180\u2013195.","journal-title":"Drug Resist. Updat."},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.diagmicrobio.2011.07.007","article-title":"Wild-type MIC distributions and epidemiological cutoff values for fluconazole, posaconazole and voriconazole when testing Cryptococcus neoformans by CLSI broth microdilution methods","volume":"71","author":"Pfaller MA","year":"2011","unstructured":"PfallerMA CastanheiraM DiekemaDJ MesserSA JonesRN. 2011. Wild-type MIC distributions and epidemiological cutoff values for fluconazole, posaconazole and voriconazole when testing Cryptococcus neoformans by CLSI broth microdilution methods. Diagn. Microbiol. Infect. Dis. 71:252\u2013259.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00248-12"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.2003.03281.x"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.09.112"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00156-08"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01630-08"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05502-11"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01216-08"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.3109\/13693786.2011.602126"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2006.01377.x"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00153-10"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.4.748"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.2.322"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01115-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01115-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:56:57Z","timestamp":1645462617000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01115-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1128\/AAC.01115-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.01115-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"2012-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-08-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-10-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}